Study on the risk of relapse after discontinuation of ibrutinib

Ibrutinib, this targeted anti-cancer drug, has shown significant therapeutic effects in the treatment of B-cell malignancies such as chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). However, many patients who take ibrutinib have concerns about the risk of relapse after discontinuing the drug. This article will discuss this issue in depth.

First of all, it needs to be clear that there is a real risk of recurrence after discontinuation of ibrutinib. The main mechanism of action of ibrutinib is to block the growth and spread of tumor cells by inhibiting the activity of BTK (Bruton's tyrosine kinase). However, once ibrutinib is discontinued, BTK activity may gradually resume, potentially causing tumor cells to re-grow and spread.

However, it is worth noting that the risk of recurrence is not static and is affected by many factors. The patient's disease severity, stage, and presence of high-risk factors are all important references for assessing the risk of recurrence. Generally speaking, patients with mild disease, early stage, and no high-risk factors have a relatively low risk of recurrence after discontinuation of treatment.

In addition, individual differences among patients are also important factors affecting the risk of recurrence. Everyone’s physical condition, genotype, immune status, etc. are different, and these factors may affect the metabolism and efficacy of ibrutinib in the body. Therefore, doctors need to take the patient's specific circumstances into consideration when assessing the risk of recurrence.

In order to reduce the risk of recurrence after stopping ibrutinib, patients should follow their doctor’s recommendations for standardized treatment. This includes taking your medications on time, not stopping or changing medication doses without authorization, and having regular checkups and monitoring for changes and signs of recurrence. At the same time, maintaining good living habits and mentality and enhancing the body's immunity and resistance are also important measures to prevent recurrence.

In summary, there is indeed a risk of recurrence after discontinuation of ibrutinib, but not all patients will face this risk. By standardizing treatment, regular monitoring and maintaining good living habits, patients can reduce the risk of recurrence and prolong survival. For the specific selling price of ibrutinib, it is recommended to directly consult your local pharmacy for the latest information. At the same time, affordable generic drugs are also available in overseas markets, providing patients with more treatment options.